<DOC>
	<DOCNO>NCT02473497</DOCNO>
	<brief_summary>This open label expand access protocol treatment approximately 40 adult pediatric ( define age &lt; 18 year ) patient tumor harbor either chromosomal translocation activate mutation involve ALK ROS1 gene activate genetic alteration involve cMET gene swallow crizotinib capsule may able derive benefit treatment alternative oral formulation crizotinib .</brief_summary>
	<brief_title>Crizotinib ( Xalkori ) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients</brief_title>
	<detailed_description>Crizotinib indicate U.S. treatment patient metastatic non-small cell lung cancer ( NSCLC ) whose tumor anaplastic lymphoma kinase ( ALK ) -positive detect FDA-approved test . Commercially available dosage form 250 mg 200 mg capsule . This expand access protocol ( EAP ) design provide access alternative oral formulation crizotinib patient unable swallow capsule .</detailed_description>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Histologically cytologically proven diagnosis primary metastatic malignancy positive chromosomal translocation activate mutation involve ALK ROS1 gene activate genetic alteration involve c MET gene , determine local clinical test appropriately validate accordance applicable regulatory guideline and/or practice standard ( patient tumor harbour genetic alteration may potentially benefit treatment crizotinib eg NTRK3 ETV6 fusion gene may consider case case basis subject approval sponsor ) . Inability swallow crizotinib capsule , adult patient must either feed tube place complete clinical evaluation dysphagia without reversible cause identify . At least 12 month age ( patient &lt; 12 month age evaluate case case basis discuss sponsor ) . Currently receive crizotinib , another ALK inhibitor , investigational product . Adult patient previously treat crizotinib .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>chromosomal rearrangement</keyword>
	<keyword>activate mutation</keyword>
	<keyword>activate genetic alteration</keyword>
	<keyword>genetic aberration</keyword>
	<keyword>ALK</keyword>
	<keyword>ROS1</keyword>
	<keyword>cMET</keyword>
	<keyword>crizotinib</keyword>
	<keyword>oral formulation</keyword>
</DOC>